Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Outlook Therapeutics, Inc. (OTLK)

Outlook Therapeutics sets LYTENAVA U.S. list price at $485 per vial

Neutral Impact 2 of 5 product/contract Written later

Outlook Therapeutics disclosed that on September 16, 2026, it set the wholesale acquisition cost for LYTENAVA in the United States at $485 per vial. The filing is a routine pricing disclosure and does not include sales, revenue, or guidance figures.

Key points

  • Wholesale acquisition cost for LYTENAVA in the U.S. set at $485 per vial
  • Price established on September 16, 2026
  • Disclosed in an Item 8.01 (Other Events) filing dated September 18, 2026

The filing

CompanyOutlook Therapeutics, Inc. (OTLK)
Form8-K, current report
Filed with the SECSep 18, 2026, 4:30 PM ET
Accession number0001104659-26-108952

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 18, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.